JP2022515868A5 - - Google Patents
Info
- Publication number
- JP2022515868A5 JP2022515868A5 JP2021538037A JP2021538037A JP2022515868A5 JP 2022515868 A5 JP2022515868 A5 JP 2022515868A5 JP 2021538037 A JP2021538037 A JP 2021538037A JP 2021538037 A JP2021538037 A JP 2021538037A JP 2022515868 A5 JP2022515868 A5 JP 2022515868A5
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- cancer
- tgf
- beta
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785647P | 2018-12-27 | 2018-12-27 | |
| US62/785,647 | 2018-12-27 | ||
| PCT/US2019/068499 WO2020139897A1 (en) | 2018-12-27 | 2019-12-24 | Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515868A JP2022515868A (ja) | 2022-02-22 |
| JP2022515868A5 true JP2022515868A5 (https=) | 2023-01-19 |
| JP7588074B2 JP7588074B2 (ja) | 2024-11-21 |
Family
ID=71129448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538037A Active JP7588074B2 (ja) | 2018-12-27 | 2019-12-24 | がんを治療するために、免疫チェックポイント阻害剤と組み合わせて送達されるｓｉＲＮＡを使用したＴＧＦ－ベータ１およびＣｏｘ２のサイレンシング |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210324384A1 (https=) |
| EP (1) | EP3902817A4 (https=) |
| JP (1) | JP7588074B2 (https=) |
| KR (1) | KR20220030203A (https=) |
| CN (1) | CN114144423B (https=) |
| AU (1) | AU2019414427A1 (https=) |
| BR (1) | BR112021012715A2 (https=) |
| CA (1) | CA3125285A1 (https=) |
| IL (1) | IL284412A (https=) |
| WO (1) | WO2020139897A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021061437A1 (en) * | 2019-09-12 | 2021-04-01 | Sirnaomics, Inc. | CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER |
| JP2024506240A (ja) * | 2021-01-21 | 2024-02-13 | サーナオミクス インコーポレイテッド | 皮膚がんの治療のための組成物および方法 |
| CN115463148A (zh) * | 2021-06-11 | 2022-12-13 | 圣诺生物医药技术(苏州)有限公司 | 一种用于治疗皮肤肿瘤的小干扰核酸药物组合物及制剂 |
| CN115919888A (zh) * | 2021-07-16 | 2023-04-07 | 圣诺生物医药技术(苏州)有限公司 | 一种用于治疗多种肿瘤的核酸干扰药物组合物 |
| CA3225925A1 (en) * | 2021-07-16 | 2023-01-19 | Sirnaomics, Inc. | Sirna-copolymer compositions and methods of use for treatment of liver cancer |
| WO2023086386A1 (en) * | 2021-11-09 | 2023-05-19 | Sirnaomics, Inc. | Treatment of 2019-ncov using sirnas against tgfb1 and cox2 |
| EP4437107A4 (en) * | 2021-11-22 | 2025-04-23 | Sirnaomics, Inc. | Method for inducing remodeling of adipose tissue using RNAi therapeutics |
| CN116421616B (zh) * | 2022-03-17 | 2025-08-12 | 圣诺生物医药技术(苏州)有限公司 | 一种核酸干扰药物组合物及用于治疗结直肠癌、胃癌、前列腺癌的药物 |
| CN116983322B (zh) * | 2022-09-15 | 2026-04-07 | 圣诺生物医药技术(苏州)有限公司 | 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物 |
| EP4673542A1 (en) * | 2023-03-01 | 2026-01-07 | Philipps-Universität Marburg | Plac8 antisense molecules used as a medicament |
| WO2025171164A1 (en) * | 2024-02-07 | 2025-08-14 | Board Of Regents, The University Of Texas System | Gene signatures predictive of cancer cell response to immunomodulatory therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| AU2005218759B2 (en) | 2004-02-27 | 2009-07-16 | Antisense Pharma Gmbh | Pharmaceutical composition |
| CN101060849A (zh) | 2004-11-17 | 2007-10-24 | 巴尔的摩马里兰大学 | 作为有效的siRNA载体的高分支HK肽 |
| JP2011504170A (ja) | 2007-11-06 | 2011-02-03 | サーナオミクス、インク． | 皮膚の中で平癒している瘢痕のない損傷のためのマルチ目標とされたＲＮＡｉ治療学 |
| WO2009104051A2 (en) * | 2007-12-31 | 2009-08-27 | Lu Patrick Y | Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine |
| WO2009151539A1 (en) * | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
| WO2011140285A2 (en) * | 2010-05-04 | 2011-11-10 | Sirnaomics, Inc. | Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application |
| WO2018081726A2 (en) * | 2016-10-30 | 2018-05-03 | Sirnaomics, Inc. | Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis |
| US20190290614A1 (en) * | 2016-11-09 | 2019-09-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for Reducing Recurrence of Tumors |
| CN110573166B (zh) * | 2017-03-19 | 2023-08-22 | 圣诺生物医药技术(苏州)有限公司 | 用于癌症治疗的吉西他滨衍生物 |
-
2019
- 2019-12-24 KR KR1020217023371A patent/KR20220030203A/ko not_active Ceased
- 2019-12-24 CN CN201980093031.7A patent/CN114144423B/zh active Active
- 2019-12-24 WO PCT/US2019/068499 patent/WO2020139897A1/en not_active Ceased
- 2019-12-24 EP EP19903345.7A patent/EP3902817A4/en active Pending
- 2019-12-24 BR BR112021012715-1A patent/BR112021012715A2/pt not_active IP Right Cessation
- 2019-12-24 JP JP2021538037A patent/JP7588074B2/ja active Active
- 2019-12-24 CA CA3125285A patent/CA3125285A1/en active Pending
- 2019-12-24 AU AU2019414427A patent/AU2019414427A1/en not_active Abandoned
-
2021
- 2021-06-27 IL IL284412A patent/IL284412A/en unknown
- 2021-06-28 US US17/361,109 patent/US20210324384A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515868A5 (https=) | ||
| Wang et al. | Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models | |
| JP7588074B2 (ja) | がんを治療するために、免疫チェックポイント阻害剤と組み合わせて送達されるｓｉＲＮＡを使用したＴＧＦ－ベータ１およびＣｏｘ２のサイレンシング | |
| Akl et al. | Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine | |
| Fang et al. | A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice | |
| Chan et al. | Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy | |
| Miao et al. | Inhibition of established micrometastases by targeted drug delivery via cell surface–associated GRP78 | |
| Beyer et al. | Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs | |
| KR102776457B1 (ko) | 항-cd47 작용제-기초된 난소암 요법 | |
| JP2013539468A5 (https=) | ||
| MX2011000236A (es) | Agentes de union a notch y antagonistas y metodos de uso de los mismos. | |
| Maes et al. | Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies | |
| Nandhu et al. | Development of a function-blocking antibody against fibulin-3 as a targeted reagent for glioblastoma | |
| Lu et al. | Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer | |
| Weibel et al. | Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection | |
| Wang et al. | N2E4, a monoclonal antibody targeting neuropilin-2, inhibits tumor growth and metastasis in pancreatic ductal adenocarcinoma via suppressing FAK/Erk/HIF-1α signaling | |
| KR20220015375A (ko) | Ｓｅｐｈｂ4-ｈｓａ 융합 단백질을 이용한 암의 치료 | |
| US20230227823A1 (en) | Fmrp and cancer treatment | |
| Aftabizadeh et al. | Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis | |
| Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
| Uchida et al. | Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma | |
| Wang et al. | Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma | |
| JP2020506923A (ja) | 治療方法 | |
| Kanda et al. | Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer | |
| Mouawad et al. | How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia |